Phonpen Akarawatcharangura Goo
A5072389393- SARS-CoV-2 and COVID-19 Research
- Heparin-Induced Thrombocytopenia and Thrombosis
- Peripheral Neuropathies and Disorders
- Inflammatory Myopathies and Dermatomyositis
- Systemic Sclerosis and Related Diseases
- Systemic Lupus Erythematosus Research
- COVID-19 Clinical Research Studies
- Autoimmune and Inflammatory Disorders Research
- COVID-19 Impact on Reproduction
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Reproductive System and Pregnancy
- Medical and Biological Ozone Research
- Pregnancy and Medication Impact
Memorial Hospital
2025
Queen Saovabha Memorial Institute
2023
Abstract Objectives To comprehensively compare the disease burden among patients with RA, PsA and AS using Patient-Reported Outcome Measurement Information System (PROMIS) scores to identify distinct patient clusters based on comorbidity profiles PROMIS outcomes. Methods Data from global COVID-19 Vaccination in Autoimmune Diseases (COVAD) 2 e-survey were analysed. Patients or undergoing treatment DMARDs included. (global physical health, mental fatigue 4a function short form 10a),...
Abstract Objectives Disease flares in the post–coronavirus disease 2019 (COVID-19) vaccination period represent a prominent concern, though risk factors are poorly understood. We studied these among patients with idiopathic inflammatory myopathies (IIMs) and other autoimmune rheumatic diseases (AIRDs). Methods The COVAD-1 -2 global surveys were circulated early 2021 2022, respectively, we captured demographics, comorbidities, AIRDs details, COVID-19 infection history details. Flares of IIMs...
Abstract Limited evidence on long-term COVID-19 vaccine safety in patients with idiopathic inflammatory myopathies (IIMs) continues to contribute hesitancy. We studied delayed-onset adverse events (AEs) IIMs, other systemic autoimmune and disorders (SAIDs), healthy controls (HCs), using data from the second Vaccination Autoimmune Diseases (COVAD) study. A validated self-reporting e-survey was circulated by COVAD study group (157 collaborators, 106 countries) Feb–June 2022. collected...
We investigated coronavirus disease 2019 (COVID-19) vaccine safety in pregnant and breastfeeding women with autoimmune diseases (AID) the COVID-19 Vaccination Autoimmune Diseases (COVAD) study.
The safety profile of COVID-19 vaccination is well documented, but hesitancy among people with immune-mediated inflammatory diseases, often immunocompromised, remains high, partially due to a scarcity data on over longer term. We herein aimed assess delayed adverse events (DAEs) occurring >7 days after in systemic lupus erythematosus (SLE) versus other rheumatic autoimmune diseases (rAIDs), non-rheumatic AIDs (nrAIDs), and healthy controls (HCs).Self-reported were captured within the...
<h3>Objective</h3> The management of systemic lupus erythematosus (SLE) relies on accurately evaluating disease activity. However discordance between physician and patient perceptions activity are frequently observed. With the increasing prevalence virtual consultations, understanding factors contributing to this in perceived is crucial. This global study aimed identify predictors patient-physician a large SLE population. <h3>Methods</h3> Data was collected from COVAD study, collaborative...
Abstract This study aimed to assess COVID-19 vaccination-related AEs in patients with rheumatoid arthritis (RA), the Vaccination Autoimmune Diseases (COVAD)-2 study. An online international cross-sectional survey captured self-reported data on adverse events (AEs) people RA, autoimmune diseases (AIDs; rheumatic [r] and non-rheumatic [nr]) healthy controls (HCs). The was circulated by COVAD group, comprising 157 collaborators across 106 countries, from February June 2022. Delayed among RA...
Abstract Objective To determine the occurrence of breakthrough COVID-19 infections (BIs) in patients with systemic lupus erythematosus (SLE) compared other rheumatic autoimmune diseases (rAIDs), non-rheumatic (nrAIDs), and healthy controls (HCs). Methods The study was based on data from 7035 fully vaccinated respondents to online COVAD questionnaire SLE (N = 852), rAIDs 3098), or nrAIDs 414), HCs 2671). BI defined as infection occurring individuals ≥ 2 doses (or 1 dose J&J) 14 days after...
Abstract Objectives The objective of this study was to explore the prevalence, characteristics and risk factors COVID-19 breakthrough infections (BIs) in idiopathic inflammatory myopathies (IIMs) using data from Vaccination Autoimmune Diseases (COVAD) study. Methods A validated patient self-reporting e-survey circulated by COVAD group collect on infection vaccination 2022. BIs were defined as occurring ≥14 days after two vaccine doses. We compared BI severity among patients with IIMs, other...
<h3>Background</h3> Although many studies have been conducted within COVID-19, there are still unanswered questions regarding breakthrough infections (BTIs), particularly in patients with systemic lupus erythematosus (SLE). We aimed to determine the occurrence of COVID-19 SLE versus other autoimmune rheumatic diseases (AIRDs), non-rheumatic (nrAIDs), and healthy controls (HCs). <h3>Methods</h3> The study was based on data from COVAD questionnaire which amassed a total 10,783 complete...